EU, US Regulators Examine Birth Defect Concerns For 'One Of The Safest' HIV Drugs
Executive Summary
Four cases of birth defects associated with HIV drug dolutegravir have prompted the EU and US regulators to recommend discontinuing its use in women seeking to get pregnant until the issue is investigated further. The development comes as a surprise because dolutegravir is regarded as one of the safest and most potent drugs for HIV treatment.